Felbinac intravenous - Shijiazhuang Yiling Pharmaceutical/Guangdong Zhongke Drug Research & DevelopmentAlternative Names: Felbinac trometamol
Latest Information Update: 30 May 2016
At a glance
- Originator Shijiazhuang Yiling Pharmaceutical
- Developer Guangdong Zhongke Drug Research & Development; Shijiazhuang Yiling Pharmaceutical
- Class Nonsteroidal anti-inflammatories; Phenylacetates
- Mechanism of Action Cyclooxygenase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- No development reported Inflammation; Pain
Most Recent Events
- 30 May 2016 Chemical information added